Search results for "MULTIPLE"

showing 10 items of 2678 documents

Carboxytherapy in dermatology.

2022

Abstract Carboxytherapy is a medical technique during which a sterile gas—carbon dioxide—is injected into the subdermal tissue. The utility of carbon dioxide injections has enhanced the practical relevance of carboxytherapy as a method for the management of multiple disorders. We have evaluated its use in the treatment of dermatologic conditions by searching electronic databases (ie, MEDLINE and PubMed) for contributions in the English language through January 2021. Carboxytherapy provides an attractive aesthetic option in skin rejuvenation, atrophic scars, striae distensae (stretch marks), cellulite-fibrolipodystrophy adhesions after liposuction, and certain types of alopecia. We discuss t…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentMEDLINEAtrophic scarsEnglish languageDermatologyCarbon Dioxidemedicine.diseaseDermatologyMultiple disordersStretch marksLiposuctionmedicineStriae distensaeHumansmedicine.symptomCellulitebusinessStriae DistensaeRejuvenationSkinClinics in dermatology
researchProduct

An overview of randomized controlled trials on endovascular treatment for chronic cerebrospinal venous insufficiency in multiple sclerosis patients

2020

AbstractAbout ten years ago it was hoped that venous angioplasty for abnormal veins, primarily the internal jugular veins, will be a much awaited treatment for multiple sclerosis. Yet, a majority of randomized clinical trials on endovascular treatment for chronic cerebrospinal venous insufficiency did not reveal clinical efficacy of these procedures in multiple sclerosis patients. Still, a detailed analysis of these trials suggests that they were poorly designed, underpowered and endovascular techniques used were often far from being optimal. Nonetheless, even considering weak points of these trials, it can be concluded that venous angioplasty should not be used as a routine treatment modal…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentMultiple sclerosisDisease030204 cardiovascular system & hematologymedicine.diseaseBalloonlaw.invention03 medical and health sciencesChronic cerebrospinal venous insufficiency0302 clinical medicineRandomized controlled triallawAngioplastymedicineStage (cooking)Cardiology and Cardiovascular MedicineIntensive care medicinebusinessInternal jugular vein030217 neurology & neurosurgeryPhlebologie
researchProduct

Prädiktive genetische Untersuchungen: Individualisierung von Diagnostik und Therapie bei Familien mit multipler endokriner Neoplasie Typ II

2008

BACKGROUND AND OBJECTIVE When multiple endocrine neoplasia type 2 (MEN2) is suspected, genetic tests are at the centre of screening procedures. It was the aim of this study to compare the diagnostic value of molecular biological investigations with that of conventional biochemical tests. PATIENTS AND METHODS The study cohort consisted of all 144 patients cared for in our department since 1990 with the suspected diagnosis of MEN2 (evidence of a medullary thyroid carcinoma [MTC]), coexistence of two MEN2 tumours or a family history of MEN2. 14 of the 144 patients (from 12 families) were already known to have an hereditary MTC, while the remaining 130 had been referred for further diagnostic i…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentThyroidectomyMultiple endocrine neoplasia type 2General MedicineHyperplasiamedicine.diseaseGastroenterologyThyroid carcinomaCalcitoninInternal medicineCohortmedicineFamily historybusinessScreening proceduresDMW - Deutsche Medizinische Wochenschrift
researchProduct

Early Mortality in Patients with Multiple Myeloma Treated with Novel Agents - Analysis from Polish Myeloma Study Group

2020

Background Although the introduction of novel agents improved the survival outcomes in patients with multiple myeloma (MM), some patients died within one year (early mortality, EM) following diagnosis. In this study, we evaluated the EM rate, and investigated the risk factors associated with EM in MM patients. Aims In this study we investigated risk factors associated with EM in MM patients initially treated with novel-agent containing regimen. Methods We conducted a multicenter (15 Polish sites) retrospective study a cohort of symptomatic MM pts diagnosed between October 2006 and November 2019 and living < 365 days (d) after diagnosis. All pts were dead at the time of the analysis. …

medicine.medical_specialtybusiness.operationbusiness.industryImmunologyRetrospective cohort studyCell BiologyHematologymedicine.diseaseOctapharmaBiochemistryThalidomideRegimenNovel agentsInternal medicineCohortMedicineIn patientbusinessMultiple myelomamedicine.drugBlood
researchProduct

Potential Involvement of Impaired Venous Outflow from the Brain in Neurodegeneration: Lessons Learned from the Research on Chronic Cerebrospinal Veno…

2019

About 10 years ago, the so-called chronic cerebrospinal venous insufficiency syndrome was discovered. This clinical entity, which is associated with extracranial venous abnormalities that impair venous outflow from the brain, was initially found exclusively in multiple sclerosis patients. Currently, we know that such venous lesions can also be revealed in other neurological pathologies, including Alzheimer’s and Parkinson’s diseases. Although direct causative role of chronic cerebrospinal venous insufficiency in these neurological diseases still remains elusive, in this paper, we suggest that perhaps an abnormal venous drainage of the brain affects functioning of the glymphatic system, whi…

medicine.medical_specialtychronic cerebrospinal venous insufficiencyDisease030204 cardiovascular system & hematologymultiple sclerosisjugular vein03 medical and health sciences0302 clinical medicineCerebrospinal fluidInternal medicineCranial cavitymedicineballoon angioplastyHumansPharmacologybusiness.industryMultiple sclerosisNeurodegenerationneurodegenerationBrainNeurodegenerative DiseasesGeneral Medicinemedicine.diseaseParkinson diseaseChronic cerebrospinal venous insufficiencymedicine.anatomical_structureVenous InsufficiencyRegional Blood FlowCerebrovascular CirculationChronic DiseaseCardiologyGlymphatic systemAlzheimer's diseaseAlzheimer diseaseJugular Veinsbusiness030217 neurology & neurosurgeryReviews on recent clinical trials
researchProduct

Impact of Cumulative Dose of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective …

2018

Abstract Background: Triplet-based lenalidomide plus dexamethasone (Rd) combinations have become the new standard of care for early relapse and refractory multiple myeloma (RRMM). Carfilzomib is a novel selective proteasome inhibitor (PI) with high efficacy in RRMM. The ASPIRE phase 3 trial showed the superiority of carfilzomib-based triplet (KRd compared to Rd), leading to approval of K for RRMM. However, little is known about safety and efficacy of KRd outside a clinical trial context. Experimental design and aims: In 11 Sicilian Centers belonging to the Sicilian Myeloma Network, from November 2016, when KRd regimen was approved in Italy, to June 2018, 103 consecutive RRMM patients (previ…

medicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiescomplete remissionImmunologylenalidomideadverse eventContext (language use)dexamethasoneBiochemistrychemistry.chemical_compoundMedian follow-upInternal medicinemedicinecarfilzomib dexamethasone lenalidomide multiple myeloma toxic effect adverse event bortezomib complete remission erythropoietin febrile neutropeniaMultiple myelomaLenalidomidetoxic effectcarfilzomibbusiness.industryCumulative dosebortezomibCell BiologyHematologymedicine.diseaseCarfilzomibmultiple myelomaRegimenfebrile neutropeniachemistryerythropoietinbusinessFebrile neutropeniamedicine.drug
researchProduct

Bortezomib Retreatment in Relapsed Multiple Myeloma (MM): Results from a Binational, Multicenter Retrospective Survey

2008

Abstract In myeloma therapy retreatment after successful therapy is frequently considered. Here we present pooled data from a German and Swiss multicenter, retrospective survey (26866138MMY4014). The survey started in Germany and was later extended to Switzerland. German data have already been published before. Here we report on the entire cohort of patients for the first time. For inclusion into this analysis, patients with MM had to have had preceding bortezomib treatment, resulting in at least partial remission and a second therapy with Bortezomib on relapse. The intention of this trial was to provide further evidence of the value of a retreatment with bortezomib, description of predispo…

medicine.medical_specialtyeducation.field_of_studyIntention-to-treat analysisBortezomibbusiness.industryImmunologyPopulationCell BiologyHematologymedicine.diseaseBiochemistrySurgeryTransplantationConcomitantInternal medicinemedicineAdverse effecteducationbusinessMultiple myelomaDexamethasonemedicine.drugBlood
researchProduct

Mortality in multiple sclerosis: a review

2008

This work was undertaken to evaluate studies on mortality caused by multiple sclerosis (MS), to evaluate if useful inferences can be drawn from survival studies that can be applied to clinical practice. A literature search was carried out to find epidemiological studies on MS prognosis, survival, mortality and causes of death relevant to our aim. The World Health Organization (WHO) reports on worldwide cause-specific mortality were also considered. Studies were evaluated according to the duration of the follow-up study, the year of publication and the methodology used. We evaluated MS survival from a methodological point of view and considered if time trends could be drawn from study result…

medicine.medical_specialtyeducation.field_of_studyPediatricsbusiness.industryMultiple sclerosisDisease durationPopulationmedicine.diseaseWorld healthClinical PracticeNeurologyOlder patientsEpidemiologymedicineNeurology (clinical)businessIntensive care medicineeducationCause of deathEuropean Journal of Neurology
researchProduct

Glutathione, GlutathioneS-Transferase α and π, and Aldehyde Dehydrogenase Content in Relationship to Drug Resistance in Ovarian Cancer

1997

Glutathione, glutathione S-transferases alpha and pi, and aldehyde dehydrogenase are associated with resistance to carboplatin and/or cyclophosphamide in cell lines. Therefore, we examined whether the expression of these factors in ovarian cancer tissue specimens is associated with resistance of the patients to combination chemotherapy with cyclophosphamide/carboplatin. Ovarian cancer tissue specimens were taken intraoperatively from 139 patients and frozen in liquid nitrogen, and the contents of glutathione S-transferases alpha and pi, total glutathione, and aldehyde dehydrogenase activity were determined. No association between the levels of glutathione S-transferases alpha and pi or alde…

medicine.medical_specialtyendocrine system diseasesCyclophosphamidemedicine.medical_treatmentBlotting WesternAldehyde dehydrogenaseAntineoplastic AgentsOvaryCarboplatinchemistry.chemical_compoundInternal medicineHumansMedicineAntineoplastic Agents AlkylatingCyclophosphamideGlutathione TransferaseNeoplasm StagingOvarian NeoplasmsChemotherapybiologybusiness.industryObstetrics and GynecologyCombination chemotherapyGlutathioneAldehyde DehydrogenasePrognosismedicine.diseaseCombined Modality TherapyGlutathioneDrug Resistance Multiplefemale genital diseases and pregnancy complicationsCarboplatinmedicine.anatomical_structureEndocrinologyOncologychemistryDrug Resistance Neoplasmbiology.proteinCancer researchDrug Therapy CombinationFemaleCisplatinbusinessOvarian cancermedicine.drugGynecologic Oncology
researchProduct

Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.

1994

We have analysed 118 families with inherited medullary thyroid carcinoma (MTC) for mutations of the RET proto-oncogene. These included cases of multiple endocrine neoplasia types 2A (MEN 2A) and 2B (MEN 2B) and familial MTC (FMTC). Mutations at one of 5 cysteines in the extracellular domain were found in 97% of patients with MEN 2A and 86% with FMTC but not in MEN 2B patients or normal controls. 84% of the MEN2A mutations affected codon 634. MEN 2A patients with a Cys634 to Arg substitution had a greater risk of developing parathyroid disease than those with other codon 634 mutations. Our data show a strong correlation between disease phenotype and the nature and position of the RET mutatio…

medicine.medical_specialtyendocrine system diseasesOncogene RETDNA Mutational AnalysisMolecular Sequence DataMultiple endocrine neoplasia type 2RET proto-oncogeneBiologymedicine.disease_causeProto-Oncogene MasInternal medicineProto-Oncogene ProteinsProto-OncogenesGeneticsmedicineDrosophila ProteinsHumansPoint MutationThyroid NeoplasmsMultiple endocrine neoplasiaDNA PrimersMutationBase SequencePoint mutationMultiple Endocrine NeoplasiaProto-Oncogene Proteins c-retReceptor Protein-Tyrosine KinasesExonsmedicine.diseasePhenotypeEndocrinologyPhenotypeProto-Oncogene Proteins c-retCarcinoma MedullaryCancer researchNature genetics
researchProduct